Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0191

Scientific exchange · Dr. Ximena Olsen

11 May 2026 · Virtual · Dr. Ximena Olsen, IEO Milano · MSL Luis Ortega · Lumeva

ReviewedManualENG-0191—

Capture insight from this engagement

Location: IEO Milano
Therapeutic area: Neurology
Country: Italy
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Switching between CGRP agents

Scientific content used

CGRP class review

Questions raised

No questions recorded.

Notes

Scientific exchange with primary care physician at IEO Milano. Discussed switching between cgrp agents.

Insights captured (1)

Capture insight

INS-0077Medium
Switching between CGRP agents
Switching between CGRP agents: recurring question reported by primary care physician (IT).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 2
Depth of exchange: 3
Actionability: 1

Data lineage

Source system: Manual
Sync: Entered manually in Hub
System of record: Hub
Record id: ENG-0191

Audit history (0)

All create, update and approval events for this record

No audit events in sample data